Mazdutide

Description

Mazdutide is a synthetic peptide analog that mimics the activity of oxyntomodulin, a naturally occurring gut hormone. It is currently undergoing extensive research for its potential in managing type 2 diabetes and promoting weight loss.

Overview

Mazdutide, also known as IBI362 or LY3305677, was initially developed by Eli Lilly and is now a key investigational peptide for Innovent Biologics. It is designed to mimic oxyntomodulin, a natural gut hormone that regulates appetite and glucose metabolism. Mazdutide has undergone molecular modifications to extend its half-life, allowing for convenient once-weekly administration. Extensive clinical research, particularly in China through the GLORY and DREAMS phase 3 programs, is evaluating mazdutide's efficacy in chronic weight management and type 2 diabetes. The GLORY program focuses on weight loss in overweight and obese individuals, while the DREAMS program investigates its role in glycemic control for type 2 diabetes patients. While accepted for chronic weight management in adults with obesity or overweight by China's NMPA, it has not yet received FDA approval in the United States. The peptide's mechanism of action involves activating both GLP-1 and GCG receptors. Activation of GLP-1 receptors in the pancreas stimulates insulin release and helps normalize blood sugar. In the digestive system, it delays stomach emptying, increasing satiety. In the brain, GLP-1 receptor activation suppresses appetite. Concurrently, GCG receptor activation increases energy expenditure, potentially by enhancing fat breakdown in the liver and promoting the transformation of white fat into metabolically active beige fat. Clinical trials have demonstrated significant weight reductions, with some studies showing average weight loss exceeding 15% from baseline in obese participants. Mazdutide has also shown substantial improvements in glycemic control for type 2 diabetes patients, with significant reductions in HbA1c levels. Beyond weight and glucose, research indicates that mazdutide can positively impact other metabolic markers, such as reducing blood pressure, triglycerides, and cholesterol levels. It has also shown promise in reducing liver fat content, offering potential benefits for conditions like non-alcoholic fatty liver disease (NAFLD).

Mechanism of Action

Mazdutide functions as a dual agonist, activating both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. This dual action contributes to its metabolic effects, including appetite suppression, enhanced insulin secretion, and increased energy expenditure. It also plays a role in delaying gastric emptying and promoting the conversion of white fat to beige fat.

Benefits

• •Reduces body weight
• •Improves glycemic control
• •Decreases liver fat content
• •Lowers blood pressure
• •Reduces triglyceride levels
• •Decreases total and LDL cholesterol

Dosing Notes

Typical dosages in clinical trials have ranged from 3 mg to 9 mg administered subcutaneously once weekly. Dosing may be titrated to achieve desired effects and manage potential side effects.

Reported Side Effects

• •Nausea
• •Vomiting
• •Diarrhea
• •Constipation
• •Abdominal pain

Safety Notes

Mazdutide is currently an investigational peptide, and long-term safety data are still being collected. Individuals with pre-existing medical conditions, particularly those affecting the gastrointestinal system or pancreas, should exercise caution. It is not approved by the U.S. FDA for human use and should only be used in research settings by qualified professionals.

Commonly Stacked With

Scientific References